Analysts highlight Cellebrite’s understated total addressable market and 21% annual recurring revenue growth as key drivers for the bullish call.
DA Davidson initiated coverage of Cellebrite DI (NASDAQ:CLBT) with a Buy rating and a $20 price target, citing a large, growing, and likely understated total addressable market. The firm’s bullish stance follows the company’s first-quarter 2026 results, where revenue rose 19% year-over-year to $128.3 million and subscription revenue climbed 23% to $117.9 million.
Annual Recurring Revenue reached $493.0 million, up 21% from the prior year. Earlier, Needham trimmed its price target on CLBT to $15 from $18 while maintaining a Buy rating, noting the company’s outperformance relative to consensus estimates despite a compressed valuation multiple.
The initiation aligns with Cellebrite’s guided acceleration in organic annualized recurring revenue growth, which analysts view as a catalyst for continued wallet share gains.